Syntheses, Biological and Preclinical Evaluations, and Nanoparticle Formulations of the ROS-Activatable Prodrugs of...

Area of Science:

• Oncology
• Nanomedicine
• Drug Development

Background:

• Doxorubicin (dox) is a widely used chemotherapy agent, but its clinical application is hampered by cardiotoxicity and acquired drug resistance.
• Doxazolidine (doxaz), a conjugate of doxorubicin, exhibits enhanced cytotoxicity and DNA cross-linking activity, even against resistant cancer cells.
• Previous attempts to develop doxaz prodrugs failed due to non-specific cytotoxicity and challenges in targeted activation within cancer cells.

Purpose of the Study:

• To develop and evaluate a novel reactive oxygen species (ROS)-activatable nanoparticle prodrug of doxaz, termed Doxaz-BA.
• To assess the efficacy and safety of Doxaz-BA nanoparticle formulations against drug-resistant cancers.
• To overcome the clinical translation barriers associated with doxaz, including its cytotoxicity and lack of tumor-specific activation.

Main Methods:

• Synthesis of Doxaz-BA and its derivatives.
• Formulation of Doxaz-BA into nanoparticles.
• In vitro evaluation in cancer cell cultures.
• In vivo assessment using mouse xenograft models.

Main Results:

• Doxaz-BA nanoparticles demonstrated significant cytotoxicity against cancer cells, including doxorubicin-resistant lines.
• In vivo studies showed minimal toxicity to normal tissues in mouse models.
• The ROS-activatable nature of Doxaz-BA allows for targeted drug release and enhanced anti-cancer activity.

Conclusions:

• Doxaz-BA represents a promising nanoparticle-based prodrug strategy for overcoming doxorubicin resistance and reducing systemic toxicity.
• This approach offers a potential solution for treating aggressive and incurable cancers.
• Further clinical translation of Doxaz-BA is warranted based on its efficacy and safety profile in preclinical studies.